Search results
Nanoscope Therapeutics has announced positive results from their two year randomised controlled phase 2b optogenetic therapy trial for late-stage retinitis pigmentosa (RP).
This edition includes exciting news about our Annual and Professionals’ Conferences. We hope as many of you as possible can join us in Manchester, or online, in September. You’ll also find updates about the latest research and a feature on one of our funded researchers, Dr Jörn Lakowski.
Our monthly e-Newsletter featuring the latest updates from Retina UK.
Retina UK has joined with more than 80 disability charities who have today written to the Chancellor calling for urgent support with the cost of living for disabled people.
“All the promising research makes you feel like there is light at the end of that very dark tunnel after all.”
In recent years there has, understandably, been a lot of excitement around cutting-edge therapies that target the specific genetic faults underlying inherited sight loss.
Biotechnology company Kiora Pharmaceuticals has been given the go-ahead to start in-human testing of a novel “small molecule” treatment, known as KIO-301, for advanced vision loss in retinitis pigmentosa (RP). The phase 1b clinical trial will take place in Adelaide, Australia, and will begin enrolling participants towards the end of 2022.
Your generous support allows Retina UK to fund the work of leading scientists who are increasing understanding of inherited sight loss and moving us closer to treatments.
Your doctor or genetic counsellor will spend some time asking about other people in your family to try to work out the way in which your particular faulty gene has been passed down through the generations – this is referred to as the inheritance pattern.
Genes exist inside all the cells that make up your body. They contain genetic code (DNA) and provide instructions for constructing proteins, which are the building blocks of our bodies and perform a huge variety of roles.
